When we invest, we’re invested.

Our promise to founders

There’s more to explore

Our Stories

A Masterclass in Scaling Developer-First Products With Industry Veteran Eeke de Milliano

Developers have become increasingly powerful decision makers and influencers within organizations, with purchasing powers of their own and dedicated budgets—particularly in light of the explosive growth of GenAI.

Permeable peptide graphic
Our Investment in Vilya: AI-Enabled Development of a New Class of Medicines
Joff Redfern headshot, square
Menlo Welcomes Former Atlassian CPO Joff Redfern to Our Investment Team 

is our

Opportunities and Challenges of Applying Generative AI to Designing New Drugs
Neon anvil falling on Wile E. Coyote
Menlo’s Investment in Neon: Serverless Postgres for Modern Workloads
Amy Wu headshot square
Menlo Ventures Doubles Down on Consumer Investing With New Partner Amy Wu

Video: Building Squint With Menlo Labs

Founder Devin Bhushan talks about Squint and making the leap to entrepreneurship with the help of Menlo Labs.

Squint Emerges From Menlo Labs With Funding From Sequoia and an Impressive Roster of Customers

Today, Squint revealed an impressive roster of customers that includes Volvo and Siemens, and announced $6 million in seed and pre-seed funding from Sequoia Arc, Menlo Ventures, and Menlo Labs.

Wave image generated by DALL-E
Generative AI: Lessons From Prior Waves
Anthropic graphic, square
Our Investment in Anthropic: The Foundation Layer for Generative AI
Riva founders Dag Kittlaus and Tuhin Sinha with Riva logo
Video: Building Riva With Menlo Labs
Finger pushing a button in an elevator
Refine Your Business Idea: Our Elevator Pitch for Future Founders

Video: Engineering New Drugs With Generative AI at Genesis Therapeutics

Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.

Join a

Our Investment in Luca: The AI-Driven Pricing Co-Pilot for Large E-commerce Companies
When we’re in,
we’re ALL IN.